-- 周一下午，能源股走低，纽约证券交易所能源板块指数和道富能源精选板块SPDR ETF（XLE）均下跌0.3%。 费城石油服务板块指数上涨0.4%，道琼斯美国公用事业指数上涨0.4%。 近月西德克萨斯中质原油期货价格上涨2.4%，至每桶96.66美元；全球基准布伦特原油期货价格上涨3.2%，至每桶108.71美元。亨利枢纽天然气期货价格上涨2.5%，至每百万英热单位2.59美元。 公司新闻方面，壳牌公司（SHEL）同意以现金加股票的方式收购加拿大能源公司ARC Resources，企业价值164亿美元。这家石油和天然气巨头希望借此增加其在加拿大蒙特尼盆地低成本页岩气和液化石油气生产领域的投资。壳牌股价下跌2.6%。
Related Articles
Insider Trading
Lifestance Health Group Insider Sold Shares Worth $492,400, According to a Recent SEC Filing
Robert Bessler, Director, on April 23, 2026, sold 69,899 shares in Lifestance Health Group (LFST) for $492,400. Following the Form 4 filing with the SEC, Bessler has control over a total of 1,485,228 common shares of the company, with 57,619 shares held directly and 1,427,609 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1845257/000119312526182153/xslF345X05/ownership.xml
$LFST
Research
Research Alert: CFRA Keeps Buy Opinion On Shares Of Ameriprise Financial, Inc.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We keep our 12-month target price of $550, valuing AMP shares at 12.5x our 2026 adjusted EPS estimate of $43.84 (raised by $1.34) and at 11.7x our 2027 EPS estimate of $46.90 (raised by $0.70). This compares to the three-year average forward multiple of 12x and peer average of 15.5x. AMP posted Q1 2026 adjusted operating EPS of $11.26 vs. $9.50, a 19% rise that topped our $10.12 estimate and $10.21 consensus view. Revenue growth of 11% exceeded our forecast and our 6%-10% growth forecast for 2026, while pretax adjusted operating margins expanded 130 bps to 28% on revenue gains and cost containment efforts. We now see revenue growth of 7% to 12% in 2026 and 2027. AMP also continued its substantial capital return program, returning $936M to shareholders in Q1 (70% of adjusted operating earnings) and $3.4B in 2025 (88% of earnings). Currently trading at 10.9x our 2026 EPS estimate, and with some decent revenue and earnings momentum, we view the shares as undervalued versus peer and historical averages.
$AMP
Research
Research Alert: CFRA Maintains Sell Opinion On Shares Of P&g
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our 12-month price target by $7 to $136, based on 19.5x our FY 26 EPS estimate and below the company's five-year average forward P/E multiple of 23.6x, reflecting our view of increased competition, higher commodity prices, and ambitious growth targets. We maintain our FY 26 and FY 27 EPS estimates of $6.96 and $7.27, respectively. P&G posted normalized FQ3 EPS of $1.59 vs. $1.54 in the year prior and $0.03 above consensus estimates. Net sales rose to $21.2B, representing a 7% increase that included a 4%-pt tailwind from FX. Organic sales advanced 3%, driven equally by a 2% increase in volume and 1% improvement in pricing, while mix remained neutral. Profitability metrics came under pressure during the quarter as gross margin contracted by 150 bps to 49.5%. On a core basis, gross margin declined 100 bps to 50.0%, impacted by 180 bps of unfavorable mix, 100 bps of reinvestments, 50 bps of higher tariff costs, and 10 bps of unfavorable commodity costs. We remain at Sell on shares.
$PG